The safety of fondaparinux for the prevention and treatment of venous thromboembolism.
Fondaparinux is the first synthetic selective Factor Xa inhibitor. Along with its antithrombotic efficacy, the safety of fondaparinux has been documented in several Phase II and III clinical trials, including the prevention of venous thromboembolism in patients undergoing major orthopaedic surgery or high-risk abdominal surgery, or in acutely ill medical patients with restricted mobility, and the treatment of patients with deep-vein thrombosis and pulmonary embolism. In all these indications, the safety of fondaparinux used according to its registered regimen was similar to that of reference comparators. In conclusion, due to its superior efficacy and satisfactory safety, fondaparinux may substantially improve the prevention and treatment of venous thrombosis.
Turpie
Alexander G G
AG
General Division, Hamilton Health Sciences Corporation, 237 Barton Street East, Hamilton, ON, L8L 2X2, Canada. turpiea@mcmaster.ca
D000925:Anticoagulants / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000077425:Fondaparinux; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D011134:Polysaccharides / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D012307:Risk Factors; D013923:Thromboembolism / Q000188:drug therapy* / Q000517:prevention & control; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000517:prevention & control
D000925:Anticoagulants; D011134:Polysaccharides; D000077425:Fondaparinux